Skip to Main content Skip to Navigation
Journal articles

Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.

Abstract : Gemcitabine-containing regimens are among standard therapies for the treatment of advanced non-small cell lung,pancreatic, or bladder cancers. Gemcitabine is a nucleoside analogue and its cytotoxicity is correlated with incorporation into genomic DNA and concomitant inhibition of DNA synthesis. However, it is still unclear by which mechanism(s) gemcitabine incorporation leads to cell death.
Document type :
Journal articles
Complete list of metadatas

https://www.hal.inserm.fr/inserm-02438313
Contributor : Philippe Pourquier <>
Submitted on : Tuesday, January 14, 2020 - 10:54:27 AM
Last modification on : Wednesday, January 15, 2020 - 1:13:36 AM

Identifiers

  • HAL Id : inserm-02438313, version 1
  • PUBMED : 12171875

Collections

Citation

Philippe Pourquier, Christopher Gioffre, Glenda Kohlhagen, Yoshimasa Urasaki, François Goldwasser, et al.. Gemcitabine (2',2'-difluoro-2'-deoxycytidine), an antimetabolite that poisons topoisomerase I.. Clinical Cancer Research, American Association for Cancer Research, 2002, 8 (8), pp.2499-504. ⟨inserm-02438313⟩

Share

Metrics

Record views

16